Vascular endothelial growth factor in tissues of patients with IHD, before and after coronary bypass surgery
- Authors: Shevchenko Y.L1, Borshchev G.G1, Fomina V.S1, Kim K.F1
-
Affiliations:
- N.I. Pirogov National Medical and Surgical Center
- Issue: Vol 14, No 1 (2019)
- Pages: 68-71
- Section: Articles
- URL: https://genescells.ru/2313-1829/article/view/122221
- DOI: https://doi.org/10.23868/201903009
Cite item
Full Text
Abstract
We present the comparative results of the study of endothelial growth factor (VEGF) in the tissues of patients with and without coronary artery disease. Concentration of the investigated growth factor was found to be higher in tissues of patients with IHD (p<0.05). Identified high content of VEGF in adipose tissue of involutive thymus and epicardial adipose tissue was stable (without signs of decreasing concentration for 3 days). Among the potential sources of VEGF, the fluid aspirated from the drains in patients on 1 day after open myocardial revascularization was proposed. Removal of blood corpuscle from the liquid did not significantly reduce the concentration of VEGF (p>0.05), but decreased the total volume of the liquid by almost 4 times (p<0.05).
Keywords
Full Text
About the authors
Yu. L Shevchenko
N.I. Pirogov National Medical and Surgical Center
G. G Borshchev
N.I. Pirogov National Medical and Surgical Center
Email: glebcenter@mail.ru
V. S Fomina
N.I. Pirogov National Medical and Surgical Center
K. F Kim
N.I. Pirogov National Medical and Surgical Center
References
- Бокерия Л.А., Гудкова Л.Г. сердечно-сосудистая хирургия. Болезни и врожденные аномалии системы кровообращения. Москва: НЦссХ им. А.Н. Бакулева, 2012: 121.
- Neumann F.J., Sousa-Uva M., Ahlsson A. et al. ESC Scientific Document Group. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur. Heart J. 2019; 40(2): 87-165.
- Lozano I., Capin E., de la Hera J.M. et al. Diffuse Coronary Artery Disease Not Amenable to Revascularization: Long-term Prognosis. Rev. Esp. Cardiol. (Engl. Ed.) 2015; 68(7): 631-3.
- Акчурин Р.С., Ширяев А.А., Дземешкевич С.Л. и др. Оценка факторов госпитальной летальности у больных ишемической болезнью сердца с высоким операционным риском. Грудная и сердечно-сосудистая хирургия 2005; 2: 14-20.
- Deveza L., Choi J., Yang F. Therapeutic angiogenesis for treating cardiovascular diseases. Theranostics 2012; 2(8): 801-14.
- Ahn A., Frishman W.H., Gutwein A. et al. Therapeutic angiogenesis: a new treatment approach for ischemic heart disease. Part I. Cardiol. Rev. 2008; 16(4): 163-71.
- Chu H., Wang Y. Therapeutic angiogenesis: controlled delivery of angiogenic factors. Ther. Deliv. 2012; 3(6): 693-714.
- Lewis C.E., Leek R., Harris A. et al. Cytokine regulation of angiogenesis in breast cancer: the role of tumor-associated macrophages. J. Leukoc Biol. 1995; 57(5): 747-51.
- Neufeld G., Kessler O. Pro-angiogenic cytokines and their role in tumor angiogenesis. Cancer Metastasis Rev. 2006; 25(3): 373-85.
- Freedman S.B., Isner J.M. Therapeutic angiogenesis for coronary artery disease. Ann. Intern. Med. 2002; 136(1): 54-71.
- Ferrara N. Vascular endothelial growth factor. Arterioscler. Thromb. Vasc. Biol. 2009; 29(6): 789-91.
- Takeshita S., Zheng L.P., Brogi E. et al. Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J. Clin. Invest. 1994; 93(2): 662-70.
- ICH Harmonized Tripartite Guidelines for Good Clinical Practice 1996.
- Directive 91/507/EEC, The Rules Governing Medicinal Products in the European Community.
- Declaration of Helsinki, concerning medical research in humans (Recommendations Guiding Physicians in Biomedical Research Involving Human Subjects, Helsinki 1964, amended Tokyo 1975, Venice 1983, Hong Kong 1989, Somerset West 1996, Edinburgh, 2000, 64th WMA General Assembly, Fortaleza, Brazil, October 2013).
